Publications by authors named "O'Morain C"
Article Synopsis
- Bismuth quadruple therapies (BQTs) have been effective in treating Helicobacter pylori infections in Europe, particularly in the face of antibiotic resistance, with notable use increasing from 8.6% in 2013 to 39% in 2021.
- An analysis of data from nearly 50,000 patients indicated that the single-capsule BQT was the most common regimen and achieved over 90% effectiveness with certain combinations.
- Key factors that improved treatment success included adherence to the regimen, use of high-dose proton pump inhibitors, and implementing the therapy as a first-line treatment.
Article Synopsis
- A study examined how different reasons for testing for Helicobacter pylori (H. pylori) affect treatment prescriptions and their success rates across Europe from 2013 to 2023.
- Out of 53,636 cases, the most common reasons for testing included dyspepsia with normal endoscopy and various types of ulcers, with treatment effectiveness ranging from 87% to 91% based on the indication.
- Patients with ulcers and preneoplastic lesions experienced higher treatment success and compliance, while those tested for dyspepsia had higher rates of adverse effects.
Current and Future Perspectives on the Management of : A Narrative Review.
Antibiotics (Basel)
June 2024
The prevalence of , a pathogen, has decreased globally in the last decade. To date, the management of has focused on a reactive approach, whereby those diagnosed are treated with antimicrobials and acid suppression in combination. This review article provides an overview of the shift in the management of from a reactive approach towards a proactive 'screen and treat' approach; the article reflects the current pharmacological landscape for treatment by exploring similarities such as the first-line prescription of quadruple therapy in most countries and provides a summary table of the best practice guidance from Europe, Asia, and North America.
View Article and Find Full Text PDFArticle Synopsis
- - National and international increases in resistance to antimicrobials for treating Helicobacter pylori (H. pylori), particularly high clarithromycin resistance levels in Ireland, necessitated a reassessment of treatment strategies.
- - The Irish H. pylori working group (IHPWG) conducted a review using the 'GRADE' approach to develop updated management recommendations based on the latest research findings.
- - Key recommendations include using bismuth quadruple therapy as the first-line treatment in unclear or confirmed clarithromycin resistance cases, and reserving clarithromycin triple therapy for cases with confirmed susceptibility, along with specific strategies for second-line and rescue therapies.
Background: Adherence to Helicobacter pylori (H. pylori) eradication treatment is a cornerstone for achieving adequate treatment efficacy.
Objective: To determine which factors influence compliance with treatment.
Article Synopsis
- This study evaluates the effectiveness and safety of various treatments for moderate to severe ulcerative colitis (UC) using a systematic review and network meta-analysis of randomized controlled trials (RCTs).
- Researchers analyzed data from 20 RCTs involving 7660 patients to determine which treatments achieved the best clinical remission rates during maintenance therapy.
- Findings indicate that upadacitinib (30 mg/day) and etrasimod (2 mg/day) are the most effective for different patient treatment approaches, while tofacitinib (10 mg) and infliximab (3.5 mg/Kg Q8W) offer the best overall efficacy-safety profiles.
Article Synopsis
- The study evaluated the global prevalence of Helicobacter pylori (H pylori) infection in adults and children/adolescents, linking it to gastric cancer rates.
- After reviewing nearly 17,000 articles, researchers found that H pylori infection prevalence dropped from 52.6% to 43.9% in adults but remained at 35.1% in children and adolescents from 2015 to 2022.
- The decline in H pylori in adults was significant in certain regions, while the relationship between H pylori prevalence and decreasing gastric cancer incidence prompts the need for further large-scale clinical trials to confirm these findings.
Background: Outcomes after ileocolonic resection in Crohn's disease [CD] are heterogeneous, and a clear definition of postoperative recurrence remains to be determined. Our Endpoints Working Group of the International Organization for the study of Inflammatory Bowel Disease [IOIBD] aimed to standardise postoperative outcomes, to discuss which endpoints should be used for postoperative clinical trials, and to define those which could be used in trials or registries.
Methods: Based on a systematic review of the literature, recommendations and statements were drafted and sent to all IOIBD members for a first round of voting.
Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management.
United European Gastroenterol J
February 2024
Article Synopsis
- - The management of Helicobacter pylori infection involves a combination of proton pump inhibitors (PPIs) and antibiotics to effectively eradicate the bacteria, as evaluated by the European Registry on Helicobacter pylori management (Hp-EuReg).
- - Analysis of data from 36,579 patients across five countries revealed that 14-day treatments with specific antibiotic combinations and high-dose PPIs resulted in optimal effectiveness, while 10- and 14-day therapies with high-dose PPIs were also successful.
- - The study concludes that for first-line treatment, the use of high-dose PPIs is recommended, especially in certain combinations and durations, while shorter 7-day therapies showed suboptimal results.
The prevalence of Helicobacter pylori remains high in the older population. Specific age-related peculiarities may impact the outcomes of H. pylori treatment.
View Article and Find Full Text PDFThe segmentation of patients into homogeneous groups could help to improve eradication therapy effectiveness. Our aim was to determine the most important treatment strategies used in Europe, to evaluate first-line treatment effectiveness according to year and country. : All first-line empirical treatments registered at AEGREDCap in the European Registry on management (Hp-EuReg) from June 2013 to November 2022.
View Article and Find Full Text PDFArticle Synopsis
- A study evaluated the effectiveness and safety of single capsule bismuth quadruple therapy (scBQT) administered three times a day, as opposed to the recommended four times a day schedule, focusing on ease of adherence.
- Out of 3,712 cases analyzed, the three times a day regimen showed a higher cure rate of 94% compared to 91% for the four times a day schedule, though adherence and safety were similar.
- The findings suggest that the three times a day scBQT regimen is more effective, with factors like treatment adherence and the type of proton pump inhibitor used being significant predictors of infection cure.
Article Synopsis
- Scientists are finding new ways to test for colorectal cancer that are easier and less invasive than traditional methods.
- A group of experts updated the rules for how to evaluate these new tests to make sure they're effective.
- The new tests should be compared to the existing reliable tests and go through several phases of research to ensure they're safe and useful in real-world situations.
Background And Aims: Several methods are available to diagnose infection. Our objective was to evaluate the tests used for both the initial diagnosis and the confirmation of eradication after treatment in Europe.
Methods: The European Registry on the management of infection is an international, multicentre, prospective, non-interventional registry aiming to evaluate the management of -infected patients in Europe.
Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting.
Lancet Gastroenterol Hepatol
September 2023
Many patients with inflammatory bowel disease (IBD) have persistent symptoms and disease activity despite the best available medical or surgical treatments. These patients are commonly referred to as having difficult-to-treat IBD and need additional therapeutic strategies. However, the absence of standard definitions has impeded clinical research efforts and comparisons of data.
View Article and Find Full Text PDFBackground: Helicobacter pylori (H. pylori) is the most common chronic bacterial infection. Treatment effectiveness remains a subject of debate considering bacterial antimicrobial resistance.
View Article and Find Full Text PDFAntimicrobial susceptibility testing for Helicobacter pylori comes of age.
Lancet Gastroenterol Hepatol
July 2023
Background: First-line therapy does not always provide a high level of eradication due to the increase of resistance to antibiotics; therefore, it remains necessary to identify the most effective rescue treatments. The purpose of this study was to evaluate the efficacy and safety of empirical furazolidone-containing regimens.
Materials And Methods: Adult infected patients empirically treated with furazolidone-containing eradication regimens were registered in an international, prospective, multicenter non-intervention European registry on management (Hp-EuReg).
Background And Aims: Patients with inflammatory bowel disease [IBD] have an attenuated response to initial COVID-19 vaccination. We sought to characterize the impact of IBD and its treatment on responses after the third vaccine against SARS-CoV-2.
Methods: This was a prospective multicentre observational study of patients with IBD [n = 202] and healthy controls [HC, n = 92].
Background: Internationally, colorectal cancer screening participation remains low despite the availability of home-based testing and numerous interventions to increase uptake. To be effective, interventions should be based on an understanding of what influences individuals' decisions about screening participation. This study investigates the association of defensive information processing (DIP) with fecal immunochemical test (FIT)-based colorectal cancer screening uptake.
View Article and Find Full Text PDFObjective: To evaluate the use, effectiveness and safety of empirical rescue therapy in third and subsequent treatment lines in Europe.
Design: International, prospective, non-interventional registry of the clinical practice of European gastroenterologists. Data were collected and quality reviewed until October 2021 at Asociación Española de Gastroenterología-Research Electronic Data Capture.
Background And Aims: The optimal management of naïve and not naïve Helicobacter pylori patients remains unclear. Therefore, it is essential to evaluate whether the actual clinical practice mirrors the indications suggested by the guidelines. This study aimed to assess the effectiveness and the safety of the empirical first- and second-line treatments prescribed to patients enroled at Italian centres participating in the European Registry on H.
View Article and Find Full Text PDFInfection is formally recognised as an infectious disease, an entity that is now included in the International Classification of Diseases 11th Revision. This in principle leads to the recommendation that all infected patients should receive treatment. In the context of the wide clinical spectrum associated with gastritis, specific issues persist and require regular updates for optimised management.
View Article and Find Full Text PDFBackground: Randomized clinical trials and meta-analyses, primarily from Asian countries, have reported good effectiveness with high-dose dual therapy (HDDT) including a proton pump inhibitor (PPI) and amoxicillin when prescribed as first-line or rescue treatment. However, combining amoxicillin with PPIs in the 1990s in several European countries yielded suboptimal results.
Methods: An international, multicenter, prospective non-interventional Registry (Hp-EuReg) aimed to evaluate the decisions and outcomes of management by European gastroenterologists.